Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Innova Market Insights conducted a consumer trends research regarding GLP-1 drugs
The Reuters report on a head-to-head trial against tirzepatide (February 2026) noted CagriSema did not meet a non-inferiority threshold against tirzepatide on average weight loss at 84 weeks
"Is it a subscription?" No
The set includes monoammonium glycyrrhizinate, L-cysteine hydrochloride hydrate, vitamins B2, B6, and C, biotin, glutathione, and tranexamic acid
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28-week, multicentre, double-blind, phase 3, randomised controlled trial
US$ 22.82
US$ 20.36
US$ 28.01
US$ 20.62
US$ 27.32
